Real-World Evidence Strategy Early Portfolio Lead Role
We are an innovative global healthcare company that focuses on immunology and has a presence in diabetes and transplant medicine. Our talented teams across different countries strive to deliver exceptional customer experiences using digital solutions, artificial intelligence, and personal expertise.
The Main Responsibilities of this role include:
* Generating key insights based on real-world data for early pipeline assets and disease areas to inform global strategies and drive informed decision-making.
* Developing an evidence strategy for Early Portfolio brands and translating business imperatives into evidence to maintain a strong market presence and ensure business continuity.
* Determining the feasibility of accessing relevant data sources to support the evidence strategy, including assessing data availability, access conditions, and suitability.
* Collaborating with stakeholders to design, align, and communicate integrated evidence generation plans globally and at country level.
* Managing the execution of real-world studies, ensuring timely delivery of results according to specified quality standards.
* Designing disease data strategies aligned with GenMed portfolio strategic recommendations and translating business needs into data requirements, exploring data availability, suitability, and access conditions.
* Analyzing data to provide actionable insights for portfolio and pipeline planning, supporting data-driven decision-making on portfolio and pipeline strategy, as well as external asset opportunities.
* Accountable for contributing to the development of early portfolio Integrated Evidence Generation Plans (IEGP) and early evidence strategies for pipeline products aiming to achieve optimal access, category-leading evidence, and lifecycle management planning.
* Supporting the alignment of strategies with stakeholders across New Product Planning, R&D, Market Access, HEOR, and other departments in portfolio and pipeline planning.
Requirements:
* A Master's degree in a quantitative field, such as pharmaco-epidemiology, biostatistics, computational science, or related area in healthcare, is required. A PhD is preferred.
* Significant experience working in Early Portfolio teams, RWE, HEOR, epidemiology, or related functions within the pharmaceutical or biotech sector.
* A proven track record of designing and executing real-world evidence studies for regulatory submissions and defining data needs for therapeutic areas or pharmaceutical products in development.
* Experience working with routinely collected health data, including structured and unstructured sources in healthcare settings within pharmaceutical companies. Significant peer-reviewed publication records in epidemiology, clinical, statistical, and/or HEOR journals are required.
* A history of working in multiple therapeutic areas, particularly in transplant, type 1/2 diabetes, and cardiovascular disease.
* Strategic and visionary thinking capabilities to shape, influence, and articulate innovative evidence generation.
* Fluency in spoken and written English, with proficiency in French or other European languages being an advantage.
This role offers the opportunity to be part of our journey towards addressing the rapid growth of chronic conditions like diabetes, cardiovascular disease, and cGVHD in transplant, making a significant impact through the application of scientific breakthroughs and collaboration.